title: Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia?
abstract: OBJECTIVE
  Our goal was to determine if any treatment of acute herpes zoster alters the incidence or duration of postherpetic neuralgia (PHN), a common sequela in elderly patients.
  
  
  METHODS
  We systematically searched MEDLINE and The Cochrane Library. We also examined the reference lists of identified trials and reviews.
  
  
  METHODS
  We included all randomized controlled trials of treatments of zoster published in English that included assessment of pain at any time after rash healing.
  
  
  METHODS
  Forty-two trials met inclusion criteria, and 2 reviewers independently evaluated them for methodologic quality and the statistical and clinical significance of results.
  
  
  RESULTS
  Four placebo-controlled trials of oral acyclovir with 692 patients provided marginal evidence for reduction in pain incidence at 1 to 3 months following zoster onset. Famciclovir significantly reduced duration but not incidence of PHN in one placebo-controlled trial of 419 patients. Valacyclovir significantly reduced duration but not incidence of PHN in one acyclovir-controlled trial of 1141 patients. Steroids had no effect on PHN. Amitriptyline for 90 days reduced pain incidence at 6 months in one placebo-controlled trial of 80 patients. A single trial of percutaneous electrical nerve stimulation (PENS) in 50 patients suggested a decrease in pain incidence at 3 and 6 months compared with famciclovir.
  
  
  CONCLUSIONS
  There is limited evidence that current interventions prevent or shorten PHN. Famciclovir and valacyclovir have been shown to reduce the duration of PHN in single published trials. Well-designed and larger trials of amitriptyline and PENS should be conducted.
authors.affiliation: Pennsylvania State University/Good Samaritan Hospital Family and Community Medicine Residency Program, Lebanon, USA. alper@earthlink.net
authors.forename: B S
authors.initials: BS
authors.lastname: Alper
authors.forename: P R
authors.initials: PR
authors.lastname: Lewis
mesh_terms: D000208:Acute Disease; D000212:Acyclovir / Q000627:therapeutic use; D000368:Aged; D000639:Amitriptyline / Q000627:therapeutic use; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006562:Herpes Zoster / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D009437:Neuralgia / Q000517:prevention & control* / Q000821:virology*; D016032:Randomized Controlled Trials as Topic; D013256:Steroids / Q000627:therapeutic use
chemical_list: D018712:Analgesics, Non-Narcotic; D000998:Antiviral Agents; D013256:Steroids; D000639:Amitriptyline; D000212:Acyclovir